Tracking Heart Rhythm and Blood Pressure in Leukemia Patients on BTK Inhibitors
Observes heart rhythm and blood pressure at home in adults with leukemia taking BTK inhibitors.
Plain-language title generated from the registry record
Registry title: Hypertension and Arrhythmias in CLL Patients Treated With BTK Inhibitors
Key facts
- Where
- Philadelphia, United StatesSee the site
Where in United States
- Abramson Cancer Center at University of PennsylvaniaPhiladelphia, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Abramson Cancer Center at Penn Medicine
- Trial code
- NCT06211413
- Record updated
- 5 October 2026
- Original description
Acalabrutinib and Zanabrutinib are highly effective drugs used to treat Chronic Lymphocytic Leukemia, but they are associated with high blood pressure and abnormal heart rhythms. SENTINEL is an observational study that will use wearable technology to monitor heart rhythm and blood pressures at home to better understand how frequently patients are experiencing high blood pressure and/or abnormal heart rhythms.Read full original descriptionShow less
A Prospective Longitudinal Cohort Study of the Incidence of Hypertension and Arrhythmias In Patients Treated With Bruton's Tyrosine Kinase Inhibitors For Chronic Lymphocytic Leukemia Using Wearable Technology
Acalabrutinib and Zanabrutinib are highly effective drugs used to treat Chronic Lymphocytic Leukemia, but they are associated with high blood pressure and abnormal heart rhythms. SENTINEL is an observational study that will use wearable technology to monitor heart rhythm and blood pressures at home to better understand how frequently patients are experiencing high blood pressure and/or abnormal heart rhythms.
Inclusion: Age ≥22; Initiation of BTK inhibitor (acalabrutinib or zanubrutinib) with or without other concurrent systemic therapy as front line or relapsed/refractory therapy for chronic lymphocytic leukemia, ordered by treating oncologist per standard of care; Normal sinus rhythm at the time of consent; Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information (in accordance with national and local patient privacy regulations).
Exclusion: Current use of a class IC or III antiarrhythmic medication; AF or other arrhythmia at the time of consent; Uncontrolled hypertension (≥140/90mmHg) at the time of consent; Inability to provide informed consent; Inability to wear a watch; Arm circumference too small (< 9 in) or arm circumference too large (> 14.5in.) to use the QardioArm cuff; Expected survival less than one year; Pregnancy at time of consent; Lack of access to a personal Apple iPhone. If the patient does not have an Apple iPhone, but another member of the patient's household has an iPhone, the patient may still be enrolled as long as there is no other Apple Watch paired with the phone.